Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study
about
Anti-nerve growth factor in pain management: current evidence[EXPRESS] Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications.Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy.
P2860
Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@ast
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@en
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@nl
type
label
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@ast
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@en
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@nl
prefLabel
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@ast
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@en
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@nl
P2093
P2860
P356
P1476
Fasinumab (REGN475), an antine ...... ts of a proof-of-concept study
@en
P2093
Paul J Tiseo
Scott Mellis
P2860
P304
P356
10.2147/JPR.S65974
P577
2014-08-22T00:00:00Z